AbbVie and OSE Immunotherapeutics Collaborate to Advance Novel Monoclonal Antibody for Chronic Inflammation Treatment

AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, have announced a strategic partnership aimed at developing OSE-230, a monoclonal antibody designed to address chronic and severe inflammation. Currently in the pre-clinical development…

Read MoreAbbVie and OSE Immunotherapeutics Collaborate to Advance Novel Monoclonal Antibody for Chronic Inflammation Treatment

FDA Prioritizes Review of EPKINLY® for Tough Follicular Lymphoma Cases

AbbVie (NYSE: ABBV) announces today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) concerning epcoritamab-bysp, a subcutaneously administered T-cell engaging bispecific antibody. This treatment targets adult patients with relapsed…

Read MoreFDA Prioritizes Review of EPKINLY® for Tough Follicular Lymphoma Cases

CHMP Grants Positive Opinion to Vertex for KALYDECO® in Treating Cystic Fibrosis in Infants Aged 1 Month and Above

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favorable opinion regarding the expansion of the label for KALYDECO® (ivacaftor) to include the treatment…

Read MoreCHMP Grants Positive Opinion to Vertex for KALYDECO® in Treating Cystic Fibrosis in Infants Aged 1 Month and Above

Bristol Myers Squibb’s Reblozyl® (luspatercept) Receives Positive CHMP Opinion for Anemia Treatment in Low- to Intermediate-Risk MDS Adults

Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Reblozyl® (luspatercept) for the treatment of adult patients with transfusion-dependent anemia due to…

Read MoreBristol Myers Squibb’s Reblozyl® (luspatercept) Receives Positive CHMP Opinion for Anemia Treatment in Low- to Intermediate-Risk MDS Adults

Celltrion Reveals New Two-Year Results of Subcutaneous Infliximab (CT-P13 SC) for Treating Inflammatory Bowel Disease (IBD) at 19th ECCO Congress

Celltrion presented encouraging findings from the extensive LIBERTY studies, including LIBERTY-CD 1 and LIBERTY-UC 2, focusing on patients with Alzheimer’s disease, Crohn’s disease (CD), or moderately to severely active ulcerative colitis (UC). Additionally, the company shared endoscopic results from a…

Read MoreCelltrion Reveals New Two-Year Results of Subcutaneous Infliximab (CT-P13 SC) for Treating Inflammatory Bowel Disease (IBD) at 19th ECCO Congress

Ironwood Pharmaceuticals to Showcase Four Abstracts at ASPEN’s 2024 Nutrition Science & Practice Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company specializing in gastrointestinal healthcare, has revealed plans to present findings from four studies examining apraglutide in adults diagnosed with short bowel syndrome with intestinal failure (SBS-IF), a condition where individuals rely on parenteral…

Read MoreIronwood Pharmaceuticals to Showcase Four Abstracts at ASPEN’s 2024 Nutrition Science & Practice Conference

FDA Prioritizes Review of Dupixent® sable for COPD Treatment Targeting Type 2 Inflammation

The U.S. Food and Drug Administration (FDA) has given priority review status to the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab), marking its sixth potential indication. This review targets its use as an add-on maintenance treatment for specific adult…

Read MoreFDA Prioritizes Review of Dupixent® sable for COPD Treatment Targeting Type 2 Inflammation

Sanofi’s Board of Directors Recommends Clotilde Delbos, Anne-Françoise Nesmes, and John Sundy as Independent Directors

Sanofi’s Board of Directors has announced its intentions for the upcoming General Shareholder Meeting on April 30, 2024. The board proposes the renewal of Rachel Duan and Lise Kingo’s terms, alongside the appointment of Clotilde Delbos, Anne-Françoise Nesmes, and John…

Read MoreSanofi’s Board of Directors Recommends Clotilde Delbos, Anne-Françoise Nesmes, and John Sundy as Independent Directors